Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 50Breast Neoplasms 25Neoplasms 6Neoplasm Metastasis 3Prostate Adenocarcinoma 2Breast Neoplasms, Male 2Advanced Breast Cancer 2Recurrence 1Primary Ovarian Insufficiency 1PSA Level Greater Than Two 1Osteitis Deformans 1Lymphatic Metastasis 1Infertility 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Advanced Metastatic Breast Cancer 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone-sensitive Metastatic Breast Cancer × Goserelin × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡